EAN 2022 | Updates on levodopa infusion therapies for advanced Parkinson’s disease

Administration of levodopa/carbidopa by continuous duodenal infusion and subcutaneous (SC) apomorphine are two common infusion therapies to control motor fluctuations in patients with advanced Parkinson’s disease (PD). Carlo Colosimo, MD, Santa Maria University Hospital, Terni, Italy, shares advances in infusion therapies for advanced PD. Recently a new drug application for the continuous SC infusion of foslevodopa/foscarbidopa was submitted to the FDA. The results are promising, and notably, the patient acceptability is expected to be better than with current levodopa/carbidopa formulations that require a percutaneous endoscopic gastrostomy, which is an invasive procedure. The availability of SC levodopa/carbidopa will represent a significant advancement in the treatment of patients with late PD. This interview took place at the European Academy of Neurology (EAN) 2022 Congress in Vienna, Austria.